scholarly journals Histologic variants of acinar prostate carcinomas: Clinicopathologic importance

2020 ◽  
pp. 36-46
Author(s):  
Harmanjot Singh ◽  
Ziad M. El-Zaatari ◽  
Jae Y. Ro

Acinar carcinoma comprises more than 90% of prostatic adenocarcinomas and is characterized by a small gland proliferation with an infiltrative growth pattern. The numerous, variably-defined histological variants of prostatic adenocarcinoma can prove to be diagnostic challenges and show prognostic differences when compared to the usual acinar carcinoma, thus emphasizing the importance in accurate recognition. Variants of acinar prostatic adenocarcinoma include the atrophic, pseudohyperplastic, microcystic, foamy gland, mucinous (colloid), signet ring-like cell, pleomorphic giant cell, and sarcomatoid variants. The atrophic, pseudohyperplastic, microcystic, and foamy gland variants can be challenging to diagnose due to their deceptively benign appearance. While the atrophic, pseudohyperplastic, microcystic, and foamy gland variants usually present as low-grade malignancies (Gleason score 6-7), the mucinous (colloid), signet ring-like cell, pleomorphic giant cell, and sarcomatoid variants often present as high-grade malignancies (Gleason score >7) and are usually associated with a worse prognosis. Small cell carcinoma is not considered as a variant of acinar carcinoma, is classified under neuroendocrine tumors, and is recommended not to be assigned a Gleason score. Small cell carcinoma is often preceded by a diagnosis of acinar adenocarcinoma, rarely presents as a de novo tumor, and, as in other organs systems has an aggressive clinical course. In this review article, we discuss variants of prostatic acinar carcinomas and briefly discuss small cell carcinoma. Awareness of variants of acinar prostate carcinoma and their clinicopathologic features is essential to rendering an accurate diagnosis and clinical management of patients with these tumors.

Rare Tumors ◽  
2011 ◽  
Vol 3 (3) ◽  
pp. 95-97
Author(s):  
Vasileios Sakalis ◽  
Anastasia Gkotsi ◽  
Efrosyni Mylonaki ◽  
Aphroditi Pantzaki ◽  
Stavros Charalambous ◽  
...  

Small cell carcinoma (SCC) or microcytic carcinoma of the urinary bladder is a rare entity comprising approximately 0.5% of all bladder tumors. Due to its rarity, no prospective studies evaluating the most effective treatment have been published in the medical literature. Several cases of bladder SCC have been presented so far. We describe our case report and we revise the recent literature. Our patient was diagnosed with pure bladder SCC and prostatic adenocarcinoma. After the initial and complete transurethral resection of the bladder tumour (TUR-BT), he underwent a thorax and mediastinum computer tomography (CT) examination to exclude primary pulmonary small cell carcinoma and a bone scan scintigraphy for staging purposes. He received a three 14-day cycles of Cisplatin-containing chemotherapeutic schema and a single dose of Luteinizing-Hormone Releasing hormone (LHRH) analogue injection after 14 days of bicalutamide administration. The patient is followed for 24 months without any signs of bladder SCC recurrence or biochemical or local relapse from prostatic adenocarcinoma.


2012 ◽  
Vol 5 (1) ◽  
pp. 53-56 ◽  
Author(s):  
AKIRA KOMIYA ◽  
KENJI YASUDA ◽  
TETSUO NOZAKI ◽  
YASUYOSHI FUJIUCHI ◽  
SHIN-ICHI HAYASHI ◽  
...  

2009 ◽  
Vol 70 (8) ◽  
pp. 2353-2356
Author(s):  
Kazunori TSUKUDA ◽  
Shoji TAKAGI ◽  
Eiji IKEDA ◽  
Saki NAKAHARA ◽  
Ryuji HIRAI ◽  
...  

2007 ◽  
Vol 57 (8) ◽  
pp. 523-528 ◽  
Author(s):  
Sohei Yamamoto ◽  
Hitoshi Tsuda ◽  
Takashi Sakano ◽  
Satoshi Aikoh ◽  
Seiichi Tamai ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document